Cargando…

The role of hepatitis B infection in anti-tuberculosis drug-induced liver injury: a meta-analysis of cohort studies

Drug-induced liver injury (DILI) is a common adverse drug reaction leading to the interruption of tuberculosis (TB) therapy. We aimed to identify whether the hepatitis B virus (HBV) infection would increase the risk of DILI during first-line TB treatment. A meta-analysis of cohort studies searched i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zheng, Jing, Guo, Mei-Hong, Peng, He-Wei, Cai, Xiao-Ling, Wu, Yun-Li, Peng, Xian-E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cambridge University Press 2020
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7770377/ https://www.ncbi.nlm.nih.gov/pubmed/33222713 http://dx.doi.org/10.1017/S0950268820002861

Ejemplares similares

Hepatitis C and not Hepatitis B virus is a risk factor for anti-tuberculosis drug induced liver injury
por: Kim, Wan Soo, et al.
Publicado: (2016)

Pharmacogenetic Study of Drug-Metabolising Enzyme Polymorphisms on the Risk of Anti-Tuberculosis Drug-Induced Liver Injury: A Meta-Analysis
por: Cai, Yu, et al.
Publicado: (2012)

Anti-tuberculosis drug-induced liver injury in patient with hepatitis B and cirrhosis: A case report
por: Aminy, Rusdi Zakki, et al.
Publicado: (2022)

Drug-Induced Liver Injury from Anti-Tuberculosis Treatment: A Retrospective Cohort Study
por: Zhao, Hong, et al.
Publicado: (2020)

Incidence, Clinical Features and Impact on Anti-Tuberculosis Treatment of Anti-Tuberculosis Drug Induced Liver Injury (ATLI) in China
por: Shang, Penghui, et al.
Publicado: (2011)

Time of Liver Function Abnormal Identification on Prediction of the Risk of Anti-tuberculosis-induced Liver Injury
por: Huang, Deliang, et al.
Publicado: (2023)

Rechallenge after anti-tuberculosis drug-induced liver injury in a high HIV prevalence cohort
por: Moosa, Muhammed Shiraz, et al.
Publicado: (2022)

N-acetyltransferase 2 genetic polymorphisms and anti-tuberculosis-drug-induced liver injury: a correlation study
por: Cheng, Fang, et al.
Publicado: (2023)

Plasma metabolomic and lipidomic alterations associated with anti-tuberculosis drug-induced liver injury
por: Wang, Ming-Gui, et al.
Publicado: (2022)

Association of UGT2B7 polymorphisms with risk of induced liver injury by anti-tuberculosis drugs in Chinese Han
por: Chen, Guo, et al.
Publicado: (2017)

Drug-induced hepatitis and the risk factors for liver injury in pulmonary tuberculosis patients
por: Gaude, Gajanan S., et al.
Publicado: (2015)

Regulation of Gut Microflora by Lactobacillus casei Zhang Attenuates Liver Injury in Mice Caused by Anti-Tuberculosis Drugs
por: Li, Yue, et al.
Publicado: (2023)

Risk factors for acute liver failure among inpatients with anti-tuberculosis drug-induced liver injury
por: Wang, Shuting, et al.
Publicado: (2018)

An Investigation of the Risk Factors Associated With Anti-Tuberculosis Drug-Induced Liver Injury or Abnormal Liver Functioning in 757 Patients With Pulmonary Tuberculosis
por: Zhong, Tao, et al.
Publicado: (2021)

Pharmacoeconomics of three Therapeutic Schemes for Anti-tuberculosis Therapy Induced Liver Injury in China
por: Chen, Yu, et al.
Publicado: (2018)

Mitochondrial DNA Variants in Patients with Liver Injury Due to Anti-Tuberculosis Drugs
por: Lee, Li-Na, et al.
Publicado: (2019)

Protective Effect of Bicyclol on Anti-Tuberculosis Drug Induced Liver Injury in Rats
por: Liu, Xin, et al.
Publicado: (2017)

Systematic review and network meta-analysis of efficacy and safety of interventions for preventing anti-tuberculosis drug induced liver injury
por: Akkahadsee, Pattaraporn, et al.
Publicado: (2023)

Efficacy and safety of milk thistle preventive treatment of anti-tuberculosis drug-induced liver injury: A protocol for systematic review and meta-analysis
por: Shi, Zhipeng, et al.
Publicado: (2020)

Hematological and liver toxicity of anti-tuberculosis drugs
por: Mirlohi, Maryam-Sadat, et al.
Publicado: (2016)

Isoniazid-specific T-cell Responses in patients with anti-tuberculosis drug related liver injury
por: Usui, Toru, et al.
Publicado: (2014)

Genetic polymorphisms in PXR and NF-κB1 influence susceptibility to anti-tuberculosis drug-induced liver injury
por: Zhang, Jingwei, et al.
Publicado: (2019)

Role of polymorphic bile salt export pump (BSEP, ABCB11) transporters in anti-tuberculosis drug-induced liver injury in a Chinese cohort
por: Chen, Ru, et al.
Publicado: (2016)

The production and sales of anti-tuberculosis drugs in China
por: Huang, Yang-Mu, et al.
Publicado: (2016)

Involvement of Cytochrome P450 1A1 and Glutathione S-Transferase P1 Polymorphisms and Promoter Hypermethylation in the Progression of Anti-Tuberculosis Drug-Induced Liver Injury: A Case–Control Study
por: He, Lei, et al.
Publicado: (2015)

Anti-tuberculosis drug development via targeting the cell envelope of Mycobacterium tuberculosis
por: Xu, Xinyue, et al.
Publicado: (2022)

Development of a prediction system for anti-tuberculosis drug-induced liver injury in Japanese patients
por: Mushiroda, Taisei, et al.
Publicado: (2016)

Leukocyte telomere length as a diagnostic biomarker for anti-tuberculosis drug-induced liver injury
por: Udomsinprasert, Wanvisa, et al.
Publicado: (2020)

Evaluation of Silymarin for management of anti-tuberculosis drug induced liver injury: a randomized clinical trial
por: Marjani, Majid, et al.
Publicado: (2019)

1431. Evaluation of Drug-induced Liver Injury in Patients Receiving Anti-tuberculosis Medications and Subsequent Management
por: Acosta, Carina, et al.
Publicado: (2022)

Drug induced liver injury: East versus West – a systematic review and meta-analysis
por: Low, En Xian Sarah, et al.
Publicado: (2020)

Combined electronic medical records and gene polymorphism characteristics to establish an anti-tuberculosis drug-induced hepatic injury (ATDH) prediction model and evaluate the prediction value
por: Zhang, Jingwei, et al.
Publicado: (2022)

TANC1 methylation as a novel biomarker for the diagnosis of patients with anti-tuberculosis drug-induced liver injury
por: Wu, Dongxue, et al.
Publicado: (2021)

Relationship of anti-tuberculosis drug-induced liver injury and genetic polymorphisms in CYP2E1 and GST
por: Santos, Eliana Abreu, et al.
Publicado: (2019)

A nomogram model to predict the risk of drug-induced liver injury in patients receiving anti-tuberculosis treatment
por: Ji, Songjun, et al.
Publicado: (2023)

iTRAQ-based proteomic analysis of hepatic tissues from patients with hepatitis B virus-induced acute-on-chronic liver failure
por: PENG, LIANG, et al.
Publicado: (2015)

Clinical characteristics of drug-induced liver injury and related risk factors
por: Lu, Ren-Jie, et al.
Publicado: (2016)

Gut microbiota characteristics of Mongolian and Han populations in anti-tuberculosis drug-induced liver injury: a population-based case–control study
por: Hao, Jinqi, et al.
Publicado: (2023)

Xiao-Yao-San protects against anti-tuberculosis drug-induced liver injury by regulating Grsf1 in the mitochondrial oxidative stress pathway
por: Bai, Zijun, et al.
Publicado: (2022)

Physical activity intervention for non-diabetic patients with non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials
por: Wang, Shu-ting, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_0hk8vq9bj5ovrlql6g7vk50h31